Other
-
R&D Tax Incentive Receipt5 May 2022
Analytica is pleased to announce the receipt of $269K from the Australian Taxation Office under the Research and Development Incentive related to the financial year to 30th June 2021.
-
Jobkeeper Payments Notification9 November 2021
A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001- jobkeeper payments disclosure by listed entity.
-
R&D Tax Incentive Receipt28 March 2019
Analytica is pleased to announce the receipt of $745k from the Australian Taxation Office under the Research and Development incentive related to the financial year to 30th June 2018.
-
PeriCoach Production Update18 December 2018
Analytica has re-opened sales in the US and its territories after resuming production with a new Contract Manufacturer, re-registering its establishments with the USFDA, and clearing the first shipment through US customs.
-
PeriCoach Manufacturing Update8 October 2018
Analytica has recently signed a manufacturing services agreement with an Australian-based contract manufacturer.
-
PeriCoach® Real-World Data Analysis Reveals Statistically Significant Reduction in Incontinence Symptoms Within 3 Weeks21 August 2018
Analysis of PeriCoach v3 real-world data conducted by an independent biostatistician reveals significant improvements in pelvic floor strength in five weeks, and reduction in urine volume and leakage episodes in only three weeks
-
USFDA Issues Warning Letters to Vaginal Rejuvenation Laser Manufacturers for Deceptive Treatment Claims1 August 2018
Analytica would like to direct shareholders to a recent USFDA announcement regarding vaginal rejuvenations.
-
New AUA and SUFA Surgical Guidelines for SUI.26 April 2017
Analytica draws the attention of shareholders to a recent release of evidence-based clinical guidelines for the surgical treatment of stress urinary incontinence.
-
PeriCoach Clinical Publication on Patient with Multiple Sclerosis and Faecal Incontinence15 September 2016
Analytica continues to execute their strategy for demonstrating PeriCoach® clinical efficacy with the company’s latest publication in the internationally regarded Journal of Urology and Research. The case study details the experience of a 70-year-old female with Multiple Sclerosis (MS) and faecal incontinence using PeriCoach as an adjunct treatment to her physical therapy sessions.
-
PeriCoach sexual health indication clarification from USFDA29 July 2016
Analytica has received clarification from the US Food and Drug Administration regarding additional marketing claims for improved sexual function in women from strengthening their pelvic floors using the PeriCoach system.
-
AutoStart Burette listed through QLD Health Tender3 June 2016
Analytica is pleased to announce that the AutoStart® infusion system product has been listed on the Queensland Health purchasing schedule.
-
PeriCoach Case Studies published in Peer Reviewed Urology Journal19 May 2016
Analytica is pleased to announce the publication of case studies in the Urologic Nursing Journal of the US Society of Urologic Nurses and Associates
-
Notice of Initial Substantial Holder2 May 2016
New substantial holder - Inov8 LLC
-
Investor Update Webcast Recording7 April 2016
Analytica is pleased to present a recording of the webcast held this morning hosted by Analytica CEO, Geoff Daly.
-
Investor Update Webcast5 April 2016
Analytica invites investors to a webcast hosted by Geoff Daly, CEO on Thursday 7 April 2016 at 9am (Brisbane time).
-
Analytica implements expenditure reduction initiatives10 March 2016
Analytica has announced a number of initiatives to reduce expenditure.
-
Notification of Expiry of Listed Options05 February 2016
Analytica advises that the attached letter has been sent to holders of Analytica listed options, as notification of the expiry of their options on 29th February 2016.
-
R and D Tax Incentive Receipt18 January 2016
Analytica is pleased to announce the receipt of $1,901k from the Australian Taxation Office under the Research and Development Incentive related to the financial year to 30th June 2015.
-
Replacement Constitution26 November 2015
Analytica replaced its constitution by a special resolution of shareholders at its AGM held 24 Nov 2015.
-
Invitation to Investment Seminars17 July 2015
Analytica invites shareholders and investors to a series of company briefings to be held around Australia from the 22 July.
-
Trading Halt6 July 2015
Analytica has requested a trading halt pending the announcement by the Company of a capital raising and a change to the Board.
-
Response to ASX Price Query6 July 2015
-
Response to ASX Appendix 4C Query13 May 2015
-
Analytica Recieves $989k R and D Tax Incentive24 October 2014
-
Shareholder Information Evenings14 October 2014
Analytica invites shareholders and investors to a series of presentation evenings to be held around Australia in the week starting 20 October.
-
Extended Voluntary Suspension from Quotation1 October 2014
Analytica has requested a further suspension from quotation pending an announcement by the Company of a capital raising.
-
Further Suspension from Quotation30 September 2014
Analytica has requested a further suspension from quotation pending an announcement by the Company of a capital raising.
-
Trading Halt29 September 2014
Analytica has requested a trading halt pending the announcement by the Company of capital raising.
-
Form 604 - Change of Interest of Substantial Shareholder4 June 2014
-
Form 60413 November 2013
Notice of change of interests of substantial holder.
-
Form 60513 November 2013
Notice of ceasing to be a substantial holder.
-
Cleansing Statement27 September 2013
Analytica is proposing to issue to eligible shareholders the opportunity to subscribe to additional shares in the Company under the Share Purchase Plan. In accordance with ASIC Class Order 09/425 Analytica has issued a 'Cleansing Statement'
-
Form 60424 July 2013
Notice of change of interests of substantial holder.
-
Trading Halt5 June 2013
Analytica Limited hereby requests a trading halt on its securities, effective immediately.
-
Receipt of Research and Development cash rebate of $487k30 May 2013
Analytica is pleased to inform the market it has received a $487k cash rebate from the Commonwealth Government. The expected receipt of these funds was set out in the quarterly 4C - quarterly cash report – released to the market in April.
-
Form 6047 September 2012
Notice of change of interests of substantial holder.
-
Notice of Exercise of Options8 August 2012
-
Form 60419 March 2012
Notice of Change of Interests of Substantial Holder.
-
Form 60316 March 2012
Notice of Initial Substantial Holder.
-
Interim Guidance10 February 2012
Analytica Limited advises that it anticipates a loss for the half year ended 31st December 2011 of approximately $1.5 Million (480k H1 2010). The result, compared to H1 2010 is attributed to increased expenditure on Research and Development, rights issue costs, write off of intellectual property together with reduction of fair value of CBio shares. Further details will be provided when the Company's half year results are finalised.
-
Consolidated Financial Statements28 September 2011
Your Directors present their report, together with the statement of the consolidated group, being the Company and its controlled entities, for the financial year ended 30 June 2011.
-
Appendix 3Z25 July 2011
Final Director's Interest Notice - David Gooch.
-
Appendix 3X25 July 2011
Initial Director's Interest Notice - Warren Brooks.
-
ASX Price Query25 February 2011
Regarding the increase in the price of Analytica's securities from 2.4 cents at the close of trade on Wednesday 23 February 2011 to an intra-day high of 3.8 cents on 25 February 2011 and the increase in the volume of securities traded over this period.